It’s been a rough nine months for Bristol-Myers Squibb, between disappointing trial results, mounting competition, and some unwelcome attention from activist investors.
But on the brighter side, the company just recruited a well-regarded cancer researcher to lead its future scientific endeavors, poaching Dr. Thomas Lynch from Massachusetts General Hospital as it works to move on from past setbacks.
About the Author Reprints
